Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
Open Access
- 18 August 2015
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 5 (8) , e621
Abstract
Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known that acamprosate inhibits glutamate action in the brain. However, AUD is a complex and heterogeneous disorder. Thus, biomarkers are required to prescribe this medication to patients who will have the highest likelihood of responding positively. To identify pharmacometabolomic biomarkers of acamprosate response, we utilized serum samples from 120 alcohol-dependent subjects, including 71 responders (maintained continuous abstinence) and 49 non-responders (any alcohol use) during 12 weeks of acamprosate treatment. Notably, baseline serum glutamate levels were significantly higher in responders compared with non-responders. Importantly, serum glutamate levels of responders are normalized after acamprosate treatment, whereas there was no significant glutamate change in non-responders. Subsequent functional studies in animal models revealed that, in the absence of alcohol, acamprosate activates glutamine synthetase, which synthesizes glutamine from glutamate and ammonia. These results suggest that acamprosate reduces serum glutamate levels for those who have elevated baseline serum glutamate levels among responders. Taken together, our findings demonstrate that elevated baseline serum glutamate levels are a potential biomarker associated with positive acamprosate response, which is an important step towards development of a personalized approach to treatment for AUD.Keywords
This publication has 51 references indexed in Scilit:
- Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of conceptTranslational Psychiatry, 2011
- Grand challenges in global mental healthNature, 2011
- 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophreniaInternational Journal of Neuropsychopharmacology, 2011
- Effect of Acamprosate on Magnetic Resonance Spectroscopy Measures of Central Glutamate in Detoxified Alcohol-Dependent IndividualsArchives of General Psychiatry, 2010
- Astrocyte Glutamine Synthetase: Importance in Hyperammonemic Syndromes and Potential Target for TherapyNeurotherapeutics, 2010
- Quantitative Metabolomics by 1H-NMR and LC-MS/MS Confirms Altered Metabolic Pathways in DiabetesPLOS ONE, 2010
- Blood–Brain Barrier Permeability for Ammonia in Patients with Different Grades of Liver Fibrosis is Not Different from Healthy ControlsJournal of Cerebral Blood Flow & Metabolism, 2010
- Neurocircuitry of AddictionNeuropsychopharmacology, 2009
- Drugs, bugs, and personalized medicine: Pharmacometabonomics enters the ringProceedings of the National Academy of Sciences, 2009
- Metabolomics: A Global Biochemical Approach to Drug Response and DiseaseAnnual Review of Pharmacology and Toxicology, 2008